113 related articles for article (PubMed ID: 37733943)
1. Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models.
Dyshlovoy SA; Hauschild J; Venz S; Krisp C; Kolbe K; Zapf S; Heinemann S; Fita KD; Shubina LK; Makarieva TN; Guzii AG; Rohlfing T; Kaune M; Busenbender T; Mair T; Moritz M; Poverennaya EV; Schlüter H; Serdyuk V; Stonik VA; Dierlamm J; Bokemeyer C; Mohme M; Westphal M; Lamszus K; von Amsberg G; Maire CL
Mol Pharm; 2023 Oct; 20(10):4994-5005. PubMed ID: 37733943
[TBL] [Abstract][Full Text] [Related]
2. Marine compound rhizochalinin shows high in vitro and in vivo efficacy in castration resistant prostate cancer.
Dyshlovoy SA; Otte K; Alsdorf WH; Hauschild J; Lange T; Venz S; Bauer CK; Bähring R; Amann K; Mandanchi R; Schumacher U; Schröder-Schwarz J; Makarieva TN; Guzii AG; Tabakmakher KM; Fedorov SN; Shubina LK; Kasheverov IE; Ehmke H; Steuber T; Stonik VA; Bokemeyer C; Honecker F; von Amsberg G
Oncotarget; 2016 Oct; 7(43):69703-69717. PubMed ID: 27626485
[TBL] [Abstract][Full Text] [Related]
3. Proteomic-based investigations on the mode of action of the marine anticancer compound rhizochalinin.
Dyshlovoy SA; Otte K; Venz S; Hauschild J; Junker H; Makarieva TN; Balabanov S; Alsdorf WH; Madanchi R; Honecker F; Bokemeyer C; Stonik VA; von Amsberg G
Proteomics; 2017 Jun; 17(11):. PubMed ID: 28445005
[TBL] [Abstract][Full Text] [Related]
4. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
5. Xihuang Pill-destabilized CD133/EGFR/Akt/mTOR cascade reduces stemness enrichment of glioblastoma via the down-regulation of SOX2.
Xu L; Duan H; Zou Y; Wang J; Liu H; Wang W; Zhu X; Chen J; Zhu C; Yin Z; Zhao X; Wang Q
Phytomedicine; 2023 Jun; 114():154764. PubMed ID: 36963368
[TBL] [Abstract][Full Text] [Related]
6. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.
Grogan PT; Sarkaria JN; Timmermann BN; Cohen MS
Invest New Drugs; 2014 Aug; 32(4):604-17. PubMed ID: 24718901
[TBL] [Abstract][Full Text] [Related]
7. Quercetin induces MGMT
Wang W; Yuan X; Mu J; Zou Y; Xu L; Chen J; Zhu X; Li B; Zeng Z; Wu X; Yin Z; Wang Q
Phytomedicine; 2023 Sep; 118():154933. PubMed ID: 37451151
[TBL] [Abstract][Full Text] [Related]
8. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
11. Tetraarsenic oxide-induced inhibition of malignant glioma cell invasion in vitro via a decrease in matrix metalloproteinase secretion and protein kinase B phosphorylation.
Gwak HS; Park MJ; Park IC; Woo SH; Jin HO; Rhee CH; Jung HW
J Neurosurg; 2014 Dec; 121(6):1483-91. PubMed ID: 25303017
[TBL] [Abstract][Full Text] [Related]
12. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma.
Liu X; Chen X; Shi L; Shan Q; Cao Q; Yue C; Li H; Li S; Wang J; Gao S; Niu M; Yu R
J Exp Clin Cancer Res; 2019 May; 38(1):219. PubMed ID: 31122294
[TBL] [Abstract][Full Text] [Related]
13. Guggulsterone from Commiphora mukul potentiates anti-glioblastoma efficacy of temozolomide in vitro and in vivo via down-regulating EGFR/PI3K/Akt signaling and NF-κB activation.
Xu HB; Chen XZ; Yu ZL; Xue F
J Ethnopharmacol; 2023 Jan; 301():115855. PubMed ID: 36280019
[TBL] [Abstract][Full Text] [Related]
14. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel 1,3,4-thiadiazole derivatives as anti-glioblastoma agents targeting the AKT pathway.
Szeliga M; Karpińska M; Rola R; Niewiadomy A
Bioorg Chem; 2020 Dec; 105():104362. PubMed ID: 33074121
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
17. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
[TBL] [Abstract][Full Text] [Related]
18. The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.
Ramis G; Villalonga-Planells R; Serra-Sitjar M; Brell M; Fernández de Mattos S; Villalonga P
Cell Oncol (Dordr); 2019 Aug; 42(4):521-536. PubMed ID: 30980364
[TBL] [Abstract][Full Text] [Related]
19. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Guo D; Reinitz F; Youssef M; Hong C; Nathanson D; Akhavan D; Kuga D; Amzajerdi AN; Soto H; Zhu S; Babic I; Tanaka K; Dang J; Iwanami A; Gini B; Dejesus J; Lisiero DD; Huang TT; Prins RM; Wen PY; Robins HI; Prados MD; Deangelis LM; Mellinghoff IK; Mehta MP; James CD; Chakravarti A; Cloughesy TF; Tontonoz P; Mischel PS
Cancer Discov; 2011 Oct; 1(5):442-56. PubMed ID: 22059152
[TBL] [Abstract][Full Text] [Related]
20. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
